Arteriovenous Malformations Market: Latest Research and Advances in Treatment
Arteriovenous malformations (AVM) refers to abnormal communications between arteries and veins that bypass the normal capillary connections. AVMs are usually present from birth and can develop in organs including the brain, lungs, liver, and spinal cord. Treatment for AVMs aims to address associated risks through procedures like embolization, radiation therapy, or surgical resection. The main advantages include reducing the risk of internal bleeding, preventing future health issues, and improving quality of life. As our understanding of AVMs has increased, more individuals are aware of treatment options to safely manage this condition.
The arteriovenous malformations market is estimated to be valued at USD 3.14 Bn in 2024 and is expected to reach USD 4.99 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031.
Key players operating in the Arteriovenous Malformations Treatment are Medtronic, Stryker, Terumo Corporation, Johnson & Johnson Services, and Penumbra.
The growing public awareness and improving diagnostic capabilities are fueling the demand for safer and effective Arteriovenous Malformations Market procedures across major markets. Various public health organizations are continuously working to spread awareness through educational campaigns and early screening drives.
Get more insights on: Arteriovenous Malformations Market
Get this Report in Japanese Language: 動静脈奇形市場
Get this Report in Korean Language: 동정맥 기형 시장
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian